Boehringer Ingelheim to acquire NBE-Therapeutics for €1.18bn
The acquisition will help expand Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumours
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Dec 20
The acquisition will help expand Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumours
11 Dec 20
With the acquisition, Gilead will get access to MYR’s advanced chronic Hepatitis Delta Virus (HDV) treatment Hepcludex
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Dec 20
Exscientia intends to use its AI-based Centaur platforms for genome scale AI-drug discovery and address critical global health…
10 Dec 20
Health Canada authorisation is based on Pfizer and BioNTech’s regulatory application, filed under the rolling submission regulatory pathway
09 Dec 20
In the interim analysis, the vaccine showed efficacy in preventing Covid-19, with no severe cases or hospitalisations after…
08 Dec 20
INO-4800 is an advanced prophylactic DNA vaccine candidate, designed to work against the activity of SARS-CoV-2, the virus…
08 Dec 20
Pfizer will leverage its extensive data and expertise, while PostEra its technology capabilities to advance the preclinical drug…
07 Dec 20
Sinovac will use the funding to further develop and expand the manufacturing capacity of its vaccine candidate CoronaVac
07 Dec 20
The UNITED study includes symptom tracking, in-home testing and in-home infusions to detect, intercept and provide early treatment…
04 Dec 20
Janssen’s BLA for amivantamab marks the first regulatory submission for the treatment of EGFR exon 20 insertion mutation-positive…